Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Filings
44 filings of KIMS since November 2024; the newest 40 below.
board outcome 15, transcript 9, presentation 9, acquisition 7, results 2, scheme 2
| Filed | Type | Subject | |
|---|---|---|---|
| 11 Nov 2026 | transcript Acquisition, Capex, Guidance, Legal, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about TranscriptAI summaryKIMS filed the transcript of its Q2 FY27 earnings conference call held on 5 November 2026 with investors and analysts. Management reported consolidated total revenue of INR1,363 crores (up 41.3% year-on-year, 14% quarter-on-quarter), EBITDA of INR279 crores (EBITDA margin 20.5%) and PAT of INR76 crores. Management said it acquired a 51% stake in Sarvottam Health Care (KIMS Trust Hospital, Kakinada) for INR80 crores and a 6% stake in Ushahkal Abhinav Specialty Hospital, Sangli, for INR15 crores. Management said it doubled capacity at KIMS Saveera Hospital, Anantapur, from 250 to 500 beds, and said the impact of trade margin rationalisation on anti-cancer drugs would be quantified after 9 November. Management attributed Andhra Pradesh margin pressure partly to a provision for doubtful debts of INR7.5-7.8 crores on government receivables, which it expects to reverse once payment is received. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Nov 2026 | scheme Acquisition | Krishna Institute of Medical Sciences Limited has informed the Exchange about Amalgamation/MergerAI summaryKrishna Institute of Medical Sciences Limited's board approved on 04 November 2026 a scheme of amalgamation merging its wholly-owned subsidiary KIMS Hospitals Private Limited (transferor) into the listed company (transferee), under the Companies Act, 2013. The transferor's turnover as on 31.03.2026 is shown as nil and its PAT as Rs. 5 million; the transferee's turnover is Rs. 17,015 million and PAT Rs. 2,607 million for the same date. No cash consideration or new share issue is involved, as the transferor is wholly owned, and the transferee's shareholding pattern is unchanged. The company states the rationale as simplifying the group structure, pooling resources, cost savings and unified decision-making. The transaction is a related party transaction exempted under Regulation 23(5)(b) of the SEBI LODR Regulations, 2015. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Nov 2026 | presentation | Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor PresentationAI summaryKrishna Institute of Medical Sciences Limited filed an investor presentation under Regulation 30 of SEBI (LODR) Regulations, 2015, dated 04 November 2026. The presentation relates to the unaudited standalone and consolidated financial results for the 2nd quarter and half-year ended 30 September 2026. The filing's pages covering the company profile, vision and mission, specialities, leadership and board do not contain the quarter's financial figures, so no revenue or profit numbers are stated here. The presentation is uploaded on the company website under the Disclosures and Analyst Calls section. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Nov 2026 | board outcome Acquisition, Legal, Management change, Results | Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryBoard of Krishna Institute of Medical Sciences Limited (KIMS) met on 04 November 2026 and approved unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2026, with Limited Review Reports. The Board approved the merger of wholly-owned subsidiary KIMS Hospitals Private Limited (transferor) into the holding company (transferee). The Board approved transaction documents for KIMS Swastha Private Limited (wholly-owned subsidiary) to enter an Operations and Management (O&M) Agreement with LOVR Institute of Medical Sciences Limited for Westfort Hospital, Thrissur. The Board approved re-appointment of Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as Chairman & Managing Director (including beyond age 70), and Ms. Dandamudi Anitha as Whole-time Director, each for a term of five years, subject to a postal ballot notice approved by the Board. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Oct 2026 | acquisition Acquisition, Capex | Krishna Institute of Medical Sciences Limited has informed the Exchange about AcquisitionAI summaryKrishna Institute of Medical Sciences (KIMS) filed an intimation under Regulation 30 of SEBI LODR on 06 October 2026 that its Board approved acquiring an equity stake in Splendid Hospitals Private Limited (Kompally) by investing up to Rs. 40.00 Cr through primary infusion. KIMS will acquire up to 22% of the equity shares of Rs. 10 each, for an aggregate consideration of up to Rs. 40.00 Crore, paid in cash, based on a valuation report by BDO Valuation Advisory LLP dated 05 October 2026. Splendid Hospitals, incorporated on 20 September 2022 and based in Kompally, Telangana, reported FY26 turnover of Rs. 1.39 Cr, PAT of Rs. -8.92 Cr and net worth of Rs. 38.69 Cr. KIMS is the O&M partner of the target and describes the investment as a strategic investment; the acquisition is not a related party transaction and no governmental or regulatory approvals are required. Completion is indicatively expected on or before 31 March 2027. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Oct 2026 | acquisition Acquisition | Krishna Institute of Medical Sciences Limited has informed the Exchange about AcquisitionAI summaryKIMS (Krishna Institute of Medical Sciences) filed an intimation under Regulation 30 of SEBI LODR that its Board, at a meeting on 06 October 2026, approved acquiring up to 51% equity stake in Sarvottam Health Care Private Limited (Kakinada), an O&M entity, by investing up to Rs. 80.00 Cr. Target company operates "Trust Multi Speciality Hospital" with 183 beds in Kakinada, Andhra Pradesh; FY26 turnover Rs. 84.83 Cr, PAT Rs. 70.55 Cr, net worth Rs. 50.30 Cr. KIMS will acquire up to 21,72,713 equity shares of Rs. 10 each (51.00%) for cash, based on a valuation report by BDO Valuation Advisory LLP dated 05 October 2026. Completion is indicatively expected on or before 31.10.2026; no governmental or regulatory approvals are required; the acquisition is not a related party transaction. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Oct 2026 | acquisition Acquisition | Krishna Institute of Medical Sciences Limited has informed the Exchange about AcquisitionAI summaryKrishna Institute of Medical Sciences (KIMS) intimated under Regulation 30 that its Board approved on 06 October 2026 the acquisition of a 6% stake in Ushahkal Abhinav Specialty Hospital LLP (Sangli), an O&M entity that KIMS already manages. Consideration is up to Rs 15 Crore in cash, by way of primary infusion, based on a valuation report by BDO Valuation Advisory LLP dated 05 October 2026; completion is indicated on or before 31 October 2026. Target entity FY 2025-26 turnover Rs 80.42 Crore, PAT Rs (23.59) Crore, networth Rs 116.42 Crore; 316 beds, expandable to over 500. The filing states the transaction is not a related party transaction and no governmental or regulatory approvals are required. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Oct 2026 | acquisition Acquisition | Krishna Institute of Medical Sciences Limited has informed the Exchange about AcquisitionAI summaryKIMS (Krishna Institute of Medical Sciences) filed an intimation under Regulation 30 of SEBI LODR on 06 October 2026 that its Board approved acquisition of up to 51% equity stake in Insignia Healthcare Private Limited (KIMS-SIKHARA), an O&M entity. Target operates a 150-bed hospital in Guntur, Andhra Pradesh, with potential to expand to 200 beds; FY 2024-25 turnover Rs. 9.68 crore, PAT Rs. -13.28 crore, net worth Rs. 243.3 crore. Shares to be acquired at Rs. 30.35 per equity share, per a valuation report by BDO Valuation Advisory LLP dated 05 October 2026; consideration in cash. Acquisition to be made as a creeping acquisition over an indicative period of 12 to 24 months; no governmental or regulatory approvals stated as required. The filing states the acquisition is not a related party transaction. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Aug 2026 | transcript Capex, Dividend / buy-back, Guidance, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about TranscriptAI summaryTranscript of KIMS Hospitals' Q1 FY27 earnings conference call held on 4 August 2026, filed on 8 August 2026. Management (Chairman Dr. Bhaskara Rao Bollineni) reported Q1 FY27 total revenue of INR 1,196 crore (up 36.1% year-on-year) and EBITDA of INR 240 crore (up 20.1% year-on-year), with PAT of INR 37 crore. Consolidated revenue from operations was INR 1,180 crore (up 35.3% year-on-year); IP volumes grew 26.6% and OP volumes grew 28.5% year-on-year. Management said a QIP raised INR 1,500 crore, of which INR 1,100 crore has been used to reduce debt, and a INR 600 crore preferential allotment to promoters is payable 25% upfront with the balance within 18 months. Management said Kerala units are at single-digit EBITDA margins for now, with mid-teens expected next financial year and around 20-22% over two to three years; the priority is stabilising recently commissioned hospitals, with greenfield expansion in core states considered next year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Aug 2026 | presentation | Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor PresentationAI summaryKrishna Institute of Medical Sciences Limited filed an investor presentation dated 03 August 2026 under Regulation 30 of SEBI LODR, covering unaudited standalone and consolidated financial results for the first quarter ended 30 June 2026. The pages provided contain the company profile, vision and mission, specialties, founder and leadership biographies, and the board of directors. The pages provided do not include the quarterly financial figures, revenue, profit or any outlook. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Aug 2026 | board outcome Acquisition, Legal, Results | Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryBoard of Krishna Institute of Medical Sciences approved unaudited standalone and consolidated results for the quarter ended 30 June 2026, with limited review reports from the statutory auditors. Standalone revenue from operations for Q1 FY27 was Rs 4,836 million, against Rs 3,734 million in the corresponding quarter of the prior year; standalone profit for the period was Rs 1,000 million-range figure as printed in the table (profit after tax reported as 607 in the prior-year column context, with the current-quarter figure partly illegible). Standalone basic EPS was Rs 1.66 for the quarter (not annualised). Board approved a loan or guarantee of up to Rs 650 crore to subsidiaries, associates, joint ventures or group entities under Section 185, subject to shareholder approval by special resolution, and a loan of up to Rs 25 crore to KIMS Hospital Enterprises Private Limited, a material subsidiary. Board approved draft O&M and Call Option Agreements with Golden Lan Solutions Private Limited and Sarwottam Healthcare Private Limited; SEBI disclosures to follow on execution. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Jun 2026 | board outcome Acquisition, Capex, Dividend / buy-back | Krishna Institute of Medical Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 13, 2026.AI summaryKrishna Institute of Medical Sciences Limited's board on 13 June 2026 approved a preferential issue of 77,02,182 warrants, each convertible into one equity share of ₹2 face value, at ₹779.00 per warrant (including a premium of ₹777.00), for aggregate cash consideration of ₹599,99,99,778. The warrants are to be allotted to promoters Dr. Abhinay Bollineni (32,09,242 warrants) and Mr. Adwik Bollineni (32,09,242 warrants), and promoter group entity Bharas Ventures LLP (12,83,698 warrants); warrants may be exercised within 18 months of allotment. The issue is subject to shareholder and regulatory approval; the board also approved convening an Extra-Ordinary General Meeting on 09 July 2026 through video conferencing. The relevant date for pricing under SEBI ICDR Regulations is 09 June 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 22 May 2026 | transcript Acquisition, Capex, Guidance, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about TranscriptAI summaryKIMS Hospitals filed the transcript of its Q4 FY26 earnings conference call held on 18 May 2026, hosted by IIFL Capital. Management reported Q4 FY26 total revenue of INR 1,084 crore (up 35.3% YoY) and EBITDA of INR 216 crore (up 6.8% YoY), with EBITDA margin at 19.9%; Q4 PAT was INR 33 crore. For FY26, management reported total revenue of INR 3,931 crore (up 28.2% YoY), EBITDA of INR 828 crore (up 1.6% YoY) and PAT of INR 242 crore versus INR 415 crore in FY25. Management said new units' EBITDA erosion was about INR 32 crore in Q4, and that EBITDA would be tracked cluster-on-cluster with quarter-on-quarter growth as the guidance. On a question about a planned INR 1,500 crore QIP, management said debt had peaked near INR 3,000 crore and proceeds would be used to retire debt and fund greenfield expansion. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 May 2026 | presentation Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor PresentationAI summaryKIMS (Krishna Institute of Medical Sciences Limited) filed an investor presentation dated May 15, 2026, under Regulation 30 of SEBI LODR, on its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026. The filing's first pages (cover letter, disclaimer, vision and mission, specialities, leadership profiles and board composition) contain no financial figures, so the results numbers, guidance or dividend details are not visible in the text provided. The presentation is uploaded on the company website under the Disclosures section, Analysts Calls schedule, PPT & Transcripts. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 May 2026 | board outcome Legal, Management change, Results | Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryBoard of Krishna Institute of Medical Sciences Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from S.R. Batliboi & Associates LLP (the filing does not state the profit or revenue figures on these pages). Board appointed M/s. Sagar & Associates as Cost Auditors for FY 2026-27 and recommended their remuneration for member approval at the AGM. Board identified Sachin Ashok Salvi (Chief Finance Officer), Nagajayanthi J.R (Company Secretary & Compliance Officer) and Bhaskar Reddy R. K (Chief Risk Officer & Chief Internal Audit) as Senior Management Personnel, effective immediately. Board approved re-designation of Adwik Bollineni from Non-Executive & Non-Independent Director to Executive & Non-Independent Director. The 24th Annual General Meeting is scheduled for Thursday, August 27, 2026. The board meeting ran from 2:00 P.M. to 5:00 P.M. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 May 2026 | board outcome Management change, Results | Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryBoard of Krishna Institute of Medical Sciences Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from S.R. Batliboi & Associates LLP (the page text does not include the reported profit or revenue figures). Board appointed M/s. Sagar & Associates as Cost Auditors for FY 2026-27 and recommended their remuneration for member approval at the AGM. Board identified Sachin Ashok Salvi (Chief Financial Officer), Nagajayanthi J.R (Company Secretary & Compliance Officer) and Bhaskar Reddy R.K (Chief Risk Officer & Chief Internal Audit) as Senior Management Personnel, effective immediately. Board approved re-designation of Adwik Bollineni from Non-Executive Non-Independent Director to Executive Non-Independent Director. The 24th Annual General Meeting is scheduled for Thursday, August 27, 2026. The board meeting ran from 2:00 PM to 5:00 PM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Mar 2026 | board outcome Capex, Dividend / buy-back | Krishna Institute of Medical Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on March 11, 2026.AI summaryKrishna Institute of Medical Sciences Limited filed the outcome of its board meeting held on 11 March 2026 (meeting 12:00 noon to 1:20 PM). The board approved raising up to ₹1,500 Crores through issuance of equity shares via one or more Qualified Institutions Placements and/or other permissible modes, subject to member and regulatory approvals and determination of issue price. The board authorised the Finance & Investment Committee to decide the terms and conditions of the fund raise. The board approved a postal ballot notice seeking members' approval for these matters; the notice will be circulated in due course. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | transcript Guidance, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about TranscriptAI summaryFiling transmits the transcript of KIMS' Q3 FY26 earnings conference call held on 09 February 2026, hosted by IIFL Capital and uploaded to the company website. Management reported Q3 FY26 consolidated revenue from operations of INR998 crores, up 29.2% year-on-year, and total revenue of INR1,003 crores; EBITDA of INR204 crores with margin of 20.4% versus 25.9% a year earlier, which management attributed mainly to EBITDA erosion from newer units. Management said Thane and Mahadevapura (Bangalore) should turn EBITDA positive or neutral towards the end of Q1 FY27, and Electronic City by end of Q3 FY26. Management put consolidated net debt at about INR2,850 crores as on 31 December 2025. Management said Nashik and Thane insurance empanelments with the top 5 insurers are expected to close before the end of Q4 FY26, and Telangana occupancy could reach 75%-80% in about three to four years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Feb 2026 | presentation Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor PresentationAI summaryKrishna Institute of Medical Sciences Limited filed its investor presentation under Regulation 30 of SEBI LODR, covering unaudited standalone and consolidated financial results for the third quarter and nine months ended 31 December 2025. The presentation is uploaded on the company website under the Analysts Calls schedule, PPT and Transcripts section. The pages provided contain the disclaimer, vision and mission, specialities list, founder and CEO profiles, and board of directors; the financial figures are not included in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Feb 2026 | acquisition Acquisition | Krishna Institute of Medical Sciences Limited has informed the Exchange about AcquisitionAI summaryKrishna Institute of Medical Sciences (KIMS) intimated under Regulation 30 that its Board approved an additional investment limit of up to Rs. 100 Crores, in one or more tranches, to acquire shares of Sarvejana Healthcare Private Limited (Sunshine Hospital) from minority shareholders. KIMS currently holds 75.53% of Sunshine Hospital, a material subsidiary; the consideration is cash, at value set by an independent valuer. Sunshine Hospital's turnover was Rs. 597.00 Cr in FY25, Rs. 464.20 Cr in FY24 and Rs. 419.44 Cr in FY23; it is an orthopedic-focused hospital in Hyderabad, Telangana, incorporated on 03/12/2008. The filing states the acquisition is not a related party transaction and that no governmental or regulatory approvals are required. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Feb 2026 | board outcome Acquisition, Results | Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryBoard of Krishna Institute of Medical Sciences Limited met on 06 February 2026 and approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with unmodified limited review reports from S.R. Batliboi & Co. LLP. The Board approved increasing the limit for acquiring shares of material subsidiary Sarvejana Healthcare Private Limited (Sunshine Hospital) from minority shareholders by up to Rs. 100 Crores, in one or more tranches, as a strategic investment. KIMS holds a 75.53% stake in Sunshine Hospital; its FY25 turnover was Rs. 597.00 Cr, and the acquisition is to be paid in cash at a value set by an independent valuer. The board meeting ran from 2:30 PM to 6:00 PM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Feb 2026 | board outcome Acquisition, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange regarding Board meeting held on February 06, 2026.AI summaryBoard of Krishna Institute of Medical Sciences Limited met on 06 February 2026 and approved unaudited standalone and consolidated financial results for the third quarter and nine months ended 31 December 2025, with unmodified limited review reports from S.R. Batliboi & Co. LLP. The Board approved increasing the limit for acquiring shares of material subsidiary Sarvejana Healthcare Private Limited (Sunshine Hospital) from minority shareholders by up to Rs. 100 crores in one or more tranches, in cash, at value set by an independent valuer. KIMS holds 75.53% of Sunshine Hospital; the target's FY25 turnover was Rs. 597.00 crore (FY24: Rs. 464.20 crore; FY23: Rs. 419.44 crore). The acquisition is not a related party transaction and no governmental or regulatory approvals are stated as required. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Dec 2025 | acquisition Acquisition | Krishna Institute of Medical Sciences Limited has informed the Exchange about the further Acquisition of shares in Sarvejana Healthcare Private LimitedAI summaryKrishna Institute of Medical Sciences Limited filed an update under Regulation 30 on the further acquisition of shares of Sarvejana Healthcare Private Limited (Sunshine Hospital), a material subsidiary. The company acquired an additional 6.94% equity stake through a secondary purchase in tranches, raising its holding from 68.59% to 75.53%. Total cost of the additional 6.94% stake is around Rs. 148.09 Cr, paid in cash based on a valuation report; the acquisition is stated as completed. Sunshine Hospital's turnover was Rs. 597.00 Cr for FY25 (FY24: Rs. 464.20 Cr; FY23: Rs. 419.44 Cr); its paid-up equity share capital is Rs. 36,51,60,900. The company described the investment as a strategic investment in its material subsidiary; the filing states it is not a related party transaction. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Nov 2025 | transcript Guidance, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about TranscriptAI summaryKIMS filed the transcript of its Q2 and H1 FY26 earnings conference call held on 10 November 2025, with the transcript also uploaded to the company website. Management reported Q2 FY26 total revenue of INR 965 crores, up 23.3% year-on-year, with EBITDA of INR 208 crores (down 6.7% year-on-year) and PAT of INR 72 crores against INR 121 crores in Q2 FY25. Management attributed the EBITDA and PAT decline mainly to four or five newly commissioned hospitals that have not yet reached EBITDA breakeven. Management guided that consolidated EBITDA margin would be around 27% to 30% over the next at least two to three years, and that ARPOB could rise from about INR 42,016 to around INR 50,000 over the next eight quarters. Management stated that Telangana is guided to grow at a high single-digit rate and Andhra at mid-teens, and that new hospitals are expected to be cost neutral by June 2026, except one Bangalore hospital not yet commissioned. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Nov 2025 | presentation | Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor PresentationAI summaryCorrigendum to the Investor Presentation uploaded on November 7, 2025, correcting an inadvertent error in the number of beds stated in that presentation. Revised data points updated: occupancy percentage (page 18), operational, census, non-census and occupancy percentages (pages 19 and 22), and the final comment under the Bengaluru section on ramp-up of AP & Karnataka units (page 25). The company states the updates are purely data corrections with no impact on its financial statements or performance; a corrected presentation has been uploaded afresh. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | presentation Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor PresentationAI summaryKrishna Institute of Medical Sciences Limited filed an investor presentation under Regulation 30 of SEBI LODR on 7 November 2025, covering unaudited standalone and consolidated financial results for the second quarter and half-year ended 30 September 2025. The presentation is uploaded on the company website under the Analysts Calls schedule, PPT and Transcripts section. The company states the presentation has not been approved or reviewed by any statutory or regulatory authority or stock exchange in India. Shareholding as on 30 September 2025: promoters 34.1%, DII 32.7%, FII 16.7%, retail and others 9.7%, retail pre-IPO 6.8%. The pages reviewed contain company profile, vision, board details and shareholding; the financial figures themselves are not included in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | scheme Acquisition, Legal | Krishna Institute of Medical Sciences Limited has informed the Exchange about Amalgamation/MergerAI summaryKrishna Institute of Medical Sciences Limited's board approved on 07 November 2025 a scheme of amalgamation merging its wholly-owned subsidiaries KIMS Hospitals Private Limited and Chalasani Hospitals Private Limited into the listed company. Turnover as on 31.03.2025 (Rs. in millions): KIMS Hospitals Private Limited 0 (PAT (5.45)); Chalasani Hospitals Private Limited 744 (PAT (98)); Krishna Institute of Medical Sciences Limited 13841 (PAT 3029). The transaction is between a holding company and its wholly-owned subsidiaries and is stated to be exempt under Regulation 23(5)(b) of the SEBI LODR Regulations. No cash consideration or new share issue is involved, and the listed company's shareholding pattern is unchanged. Stated rationale: simplification of group structure, operational efficiencies, optimised asset use and cost savings. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | board outcome Acquisition, Results | Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryBoard of Krishna Institute of Medical Sciences Limited approved unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2025 on 07 November 2025; the board meeting ran from 11:30 A.M. to 2:30 P.M. Standalone revenue from operations for the quarter ended 30 September 2025 was Rs 4,300 million, and profit after tax was Rs 588 million (figures as printed in the filing, in rupees in millions). Standalone profit after tax for the half-year ended 30 September 2025 was Rs 1,320 million on revenue from operations of Rs 8,034 million (as printed). The board also approved the merger of wholly-owned subsidiaries KIMS Hospitals Private Limited and Chalasani Hospitals Private Limited into the holding company, Krishna Institute of Medical Sciences Limited. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | board outcome Acquisition, Legal, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange regarding Board meeting held on November 07, 2025.AI summaryBoard of Krishna Institute of Medical Sciences Limited approved unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2025 on 07 November 2025, with limited review reports. Standalone revenue from operations for the quarter ended 30 September 2025 was Rs 4,300 million (figures as printed in the OCR text; quarter-on-quarter comparison in the text is partly garbled), and standalone profit for the period was reported in the statement. The Board also approved the merger of wholly-owned subsidiaries KIMS Hospitals Private Limited and Chalasani Hospitals Private Limited into the Company (the holding company, as transferee). The board meeting commenced at 11:30 A.M. and concluded at 2:30 P.M. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Aug 2025 | transcript Capex, Guidance, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about TranscriptAI summaryKIMS filed the transcript of its Q1 FY26 earnings conference call held on 7 August 2025 with investors and analysts. Management reported Q1 FY26 total revenue of INR879 crores (up 26.8% YoY), EBITDA of INR200 crores (up 8.5% YoY) at a 22.7% margin, PAT of INR85 crores and consolidated EPS of INR1.96. Management said losses from new hospitals were INR21 crores in Q1, with Nashik and Thane expected to be EBITDA neutral by end of Q2 and Q3 respectively, and Q2 new-hospital losses of INR5-10 crores incremental. Management expects the two Bangalore hospitals (about 800 beds) to be commissioned around end-August 2025 and to become EBITDA neutral within 12 months of full operations, at around 30-40% occupancy. Management expects Telangana, a mature cluster, to grow volumes at about 5-6% YoY, with Kondapur commissioning next year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Aug 2025 | presentation Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor PresentationAI summaryKIMS (Krishna Institute of Medical Sciences) filed an investor presentation under Regulation 30 of SEBI LODR, covering unaudited standalone and consolidated financial results for the first quarter ended 30 June 2025. The filing states the presentation is uploaded on the company's website under the analysts calls and PPT section. The presentation contains company overview material: vision and mission, specialties, hospital network across Telangana, Andhra Pradesh, Maharashtra and Kerala (Karnataka upcoming), and board of directors. Shareholding as on 30 June 2025 shows promoters at 34.1% and DII at 32.3%, FII at 17.1%, and retail and others at 9.6%. The pages provided do not include the quarterly financial figures or management commentary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Aug 2025 | board outcome Results | Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryBoard of Directors of Krishna Institute of Medical Sciences Limited met on 06 August 2025 (1:30 PM to 2:30 PM) and approved the unaudited standalone and consolidated financial results for the first quarter ended 30 June 2025. The Limited Review Reports, reviewed by the Audit Committee, were approved along with the results. The results are available on the company website and on the BSE and NSE websites, and will be published in newspapers as required under SEBI LODR. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Aug 2025 | board outcome Results | Krishna Institute of Medical Sciences Limited has informed the Exchange regarding Board meeting held on August 06, 2025.AI summaryBoard of Directors of Krishna Institute of Medical Sciences Limited approved the unaudited standalone and consolidated financial results for the first quarter ended 30 June 2025, together with Limited Review Reports reviewed by the Audit Committee. The board meeting held on 06 August 2025 commenced at 1:30 P.M. and concluded at 2:30 P.M. The results are available on the company website and on the BSE and NSE websites, and will be published in newspapers as required under SEBI LODR. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 May 2025 | transcript Capex, Guidance, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about TranscriptAI summaryKIMS filed the transcript of its Q4 FY25 earnings conference call held on 13 May 2025, hosted by IIFL Capital Services. Management reported FY25 total revenue of INR3,067 crores (up 22% YoY) and EBITDA of INR815 crores (up 24.7% YoY), with PAT of INR415 crores against INR336 crores in FY24. Management said Q4 FY25 total revenue was INR801 crores (up 25.7% YoY) and PAT was INR106 crores; new units incurred an EBITDA loss of INR18 crores in the quarter. Management said Nashik is expected to incur about INR15 crores of losses over 12 months, with break-even expected within 3 months after insurance empanelment, and Thane is expected to get full-fledged services from the beginning of next month. Management said Queen's NRI is running at about INR85 crores revenue annualised, with Kannur already at break-even and Kollam and Nashik expected to turn EBITDA positive in about two quarters. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2025 | presentation Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor PresentationAI summaryKIMS (Krishna Institute of Medical Sciences Limited) filed an investor presentation on its audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, dated 12 May 2025. The filing is made under Regulation 30 of SEBI (LODR) Regulations, 2015, and the presentation is uploaded to the company website. The pages provided cover the company's vision and mission, specialties, hospital network across Telangana, Andhra Pradesh, Maharashtra and Kerala (Karnataka upcoming), management and board details, and shareholding pattern as on 31 March 2025. Promoter and promoter group hold 38.8%, DII 32.4%, FII 17.2%, retail pre-IPO 7.0% and retail and others 4.6%. The pages provided do not include the financial figures or management commentary on results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2025 | board outcome Legal, Management change, Results | Outcome of Board MeetingAI summaryBoard of Krishna Institute of Medical Sciences approved audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, with an unmodified audit opinion from S.R. Batliboi & Associates LLP. Board appointed M/s. IKR & Associates as Secretarial Auditors for five years from April 01, 2025 to March 31, 2030, subject to shareholder approval at the AGM. Board appointed M/s. Sagar & Associates as Cost Auditors for FY 2025-26, with remuneration recommended for shareholder approval. Board re-appointed Mrs. Y. Prameela Rani as Independent Director for a second term of 5 years with effect from May 19, 2025. The 23rd Annual General Meeting is scheduled for Friday, August 29, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2025 | board outcome Legal, Management change, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange regarding Board meeting held on May 12, 2025.AI summaryBoard of Krishna Institute of Medical Sciences approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with S.R. Batliboi & Associates LLP's unmodified audit opinion. Board re-appointed Mrs. Y. Prameela Rani as Independent Director for a second term of 5 years, effective May 19, 2025. Board appointed IKR & Associates as Secretarial Auditors for five years from April 1, 2025 to March 31, 2030, subject to shareholder approval at the AGM. Board appointed Sagar & Associates as Cost Auditors for FY 2025-26; remuneration to be approved by members. The 23rd Annual General Meeting is scheduled for Friday, August 29, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2025 | transcript Acquisition, Capex, Management change, Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about TranscriptAI summaryKIMS filed the transcript of its Q3 FY25 earnings conference call with analysts and investors, held on 7 February 2025, and uploaded it to its website. Management (Bhaskara Rao Bollineni) reported Q3 FY25 gross revenue of INR 790 crores, up 29.7% year-on-year and 1% quarter-on-quarter; EBITDA of INR 205 crores, up 36.4% year-on-year and down 8.1% quarter-on-quarter; and PAT of INR 93 crores versus INR 77 crores in Q3 FY24. Management said the Nashik hospital incurred a loss of INR 5 crores in the quarter and is expected to break even within about one year of commencement; a one-time expenditure of INR 8-9 crores (PBDD provisions and general dues write-off) affected the quarter. Management said the other income included about INR 12.5 crores from sale of land at Chennai, and that the Bangalore second project timeline has moved from Q4 FY25 to Q2 FY26 due to execution delay. Management said the Kannur hospital in Kerala has reached breakeven within three months of opening and Kollam is expected to commence operations from April. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Feb 2025 | presentation Results | Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor PresentationAI summaryKIMS filed an investor presentation on its unaudited standalone and consolidated financial results for the third quarter and nine months ended 31 December 2024, under Regulation 30 of SEBI LODR. The filing covers the company's overview: hospitals across Telangana, Andhra Pradesh, Maharashtra and Kerala, with Karnataka upcoming, and bed counts for each facility. Shareholding as on 31 December 2024: promoter and promoter group 38.8%, DII 32.6%, FII 17.3%, retail and others 4.3%, retail pre-IPO 7.0%. The pages provided do not include the financial figures or management commentary on the quarter's results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Feb 2025 | results Results | We are submitting herewith the Integrated Filing (Financial) for the 3rd quarter and nine months ended December 31, 2024.AI summaryKrishna Institute of Medical Sciences Limited filed its Integrated Filing (Financial) for the 3rd quarter and nine months ended December 31, 2024, under SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The filing states the information is also available on the company website at kimshospitals.com under Regulation 46 of SEBI (LODR) Regulations, 2015. The pages provided contain only the cover letter and a disclosure page marking the proceeds-deviation, loan-default and audit-qualification statements as Not Applicable; the financial figures are not in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.